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We have studied p /6 INK4 mutation (by PCR-SSCP) and dele­
tion (by Southern blotting and/or multiplex PCR) in a series of 
47 biiharziasis-associated tumors from Egypt and compared the 
results with those obtained on a series of 17 established bladder 
cell lines and non-bilharziasis-associated bladder cancers from 
the Netherlands. In the cell lines we found 9 homozygous 
deletions and I mutation (59% of p /6 INK4 alterations in cell 
lines), whereas in cases from the Netherlands deletions were 
found in 4 of 22 samples. No mutations were detected in the 46 
samples screened. Interestingly, in biiharziasis-associated blad­
der cancer, deletions were present in 23 samples and mutations 
in a further 2 cases (53% of p l6 ,NK4 alteration in biiharziasis- 
associated bladder cancer). No correlation was found between 
p l6 INK4 alteration and histopathological data. Likewise, the 
same frequency of alteration was found in tumors with different 
differentiation patterns (squamous, transitional or adenocarci­
noma). Three conclusions can be drawn from our findings: (/) 
p 16INK4 alterations are more frequent in cell lines than in primary 
tumors; (if) in primary bladder tumor* (biiharziasis-associated or 
not), p /6 INK4 deletions are much more frequent than p l6 INK4 
mutations; (/#/) p /6 INK4 alterations are more frequent in biihar­
ziasis-associated bladder tumors than in other bladder tumors. 
This high frequency of deletion is not related to a specific 
histological type but to the specific etiology of these tumors.
© 1996 Wiley-Liss, Inc.
Changes in cell-cycle control are thought to be critically 
associated with cancer development. Progression from the Gi 
to the M phase is controlled by a family of enzymes called the 
cyclin-dependent kinases (CDKs) (for review see Kamb, 1995 
and references there in). The phosphoiylated down-stream 
effectors transduce the signal and lead ultimately to DNA 
synthesis and mitosis. CDK activity is dependent on positive 
regulators called cyclins and inhibited by a set of proteins 
termed CDK inhibitors. In addition, other kinases and phospha­
tases participate in the regulation of CDKs. Cyclins are low 
m.w. proteins whose function is markedly modulated during 
different phases of the cell cycle. The role played by these 
proteins in human cancer has long remained elusive. However, 
the fact that in some parathyroid adenomas, the promoter 
region of the parathyroid hormone gene is fused to the gene 
encoding cyclin Dl, provided evidence that cyclins can be 
directly involved in cancer development. Subsequent analysis 
showed that cyclin D1 can substitute totally or partially for certain 
oncogenes in cellular transformation assays in various cancers, and 
cyclin Dl has been found to be over-expressed in several cancers 
(Kamb, 1995), including bladder (Bringuier al, 1996).
Seven CDK inhibitors have been characterized so far: p57, 
p21, P27, pl9, p l8, p l6INK4 (also called CDKN2 and MTS1) 
and pl5. p l6INK4 binds specifically to CDK4 and CDK6 and 
inhibits these 2 kinases (Serrano et al., 1993). Interestingly, 
cyclin Dl activates CDK4 and CDK6. Thus, p l6INK4 is a 
specific regulator of cyclin Dl-dependent kinases. It is thus 
likely that p l6INK4 alterations can also be involved in cancer 
development. Mutations in the pl6WK4 gene were revealed in 
cell lines. In 46% of 290 studied cell lines, the/?761NK4 gene was 
found to be homozygously deleted (Kamb et al., 1994a; Nobori 
et al, 1994). Moreover, pl6mKA has been mapped to 9p21, a 
region prone to loss of heterozygozity in bladder cancer. It has 
thus been hypothesized thatp!6WK4 is the target gene in this 
region (Cairns et al., 1994; Williamson et al , 1995).
Bilharziasis is one of the most widespread diseases related 
to parasitic infections and is particularly endemic in tropical 
and subtropical countries; according to statistical data from 
the World Health Organisation (WHO), 200 million infected 
people were recorded in 74 different countries (WHO, 1985). 
Egypt is considered to be a hyperendemic area, with an overall 
prevalence rate of 50% and an early age of onset (WHO, 
1985). Bilharziasis is often associated with bladder cancer, 
which occurs with a frequency of 31% of total cancer incidence 
in Egypt (Rosin et al, 1994; Ramchurren et al, 1995). These 
tumors have a different etiology and histology than transitional­
cell carcinoma (TCC) as found in Western countries. It has 
been suggested, however, that bladder tumors of both origins 
share some molecular alterations (e.g., over-expression of 
EGFR and c-erbB-2) but also that some alterations differ in 
respect to etiology [e.g., frequent loss of retinoblastoma expres­
sion in bladder tumors found in Western countries but not in 
biiharziasis-associated tumors (Ramchurren et al, 1995)]. To 
determine whetherpI6 lNK4 is differentially involved in these 2 
types of bladder cancer, we studied p!6WKA mutations and 
deletions in biiharziasis-associated tumors from Egypt in 
comparison with established cell lines and bladder tumors 
from the Netherlands.
MATERIAL AND METHODS
In this report, we limited our analysis to exon 2 alterations in 
the /?76INK4 gene. Exons 1 and 3 were omitted since they cover 
only a minor part of the pl6MK4 gene (32%) and most 
mutations/deletions reported so far are clustered in exon 2 
(Kamb^fl/., 1994b; Nobori et al, 1994).
Cell lines and patient samples
The following bladder cancer cell lines, obtained from the 
Sloan-Kettering Cancer Center (New York, NY), were used in 
our study: SCaBER, J82, VMcubl, VMcub2, VMcub3, SW- 
800, SW-780, SW-1710, T24, RT4, RT112, 575A, 647V, 253 J, 
SD, Jon and 5637. Cells were grown in RPMI medium 
containing 10% FCS until they became subconfluent.
Forty-six frozen tumor samples from the Netherlands were 
analyzed by SSCP. In none of these was evidence for schistoso­
miasis infection found. Two were squamous-cell carcinoma 
(SCC), both grade 2, stage 3. The other tumors were TCC: 22 
were superficial and 22 invasive, 11 grade 1, 16 grade 2 and 17 
grade 3. The 2 SCC and 20 TCC (10 superficial and 10 invasive; 
4 grade 1, 7 grade 2 and 9 grade 3) were also analyzed by 
Southern blot and multiplex PCR. DNA was extracted as 
previously described (Bringuier et al, 1996). Only samples with 
more than 75% tumor material were included.
Forty-seven formalin fixed, paraffin-embedded biiharziasis- 
associated tumors were analyzed by both SSCP and multiplex 
PCR. Twenty were SCC, 20 were TCC and 5 were adenocarci-
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nomas. In 2 cases, pathological data were not available* Six 
tumors were superficial and 39 invasive* Twelve were grade 1, 
25 grade 2 and 8 grade 3. After microdissection, DNA was 
extracted according to Wright and Manos (1990).
Polymerase chain reaction
We used 2 sets of primers covering exon 2: 5'-GCAGCAC- 
CACCAGCGTGTCC-3' and 5'-GGAAATTGGAAACTG- 
GAAGC-3'; 5'-TCTGTTCTCTCTGGCAGGTC-3' and 5'- 
TCTGAGCrTrGGAAGCTCT-3'. Fifty nanograms of purified 
DNA were amplified in a total volume of 50 jxl using 50 pmol of 
sense and anti-sense primers, 200 fxM of each dNTP, lx  
amplification buffer (50 mM KC1, 10 mM TRIS, pH 8.3, 1,5 
mM MgCl2), 0.5 jxl (2.5 units) of Taq polymerase (Perkin 
Elmer, Branchburg, NJ) and 5% of DMSO. Forty cycles of 50 
sec at 94°C, 40 sec at 61°C and 40 sec at 72°C were carried out. 
PCR products were analyzed on 2% agarose gels.
Single-strand conformation polymorphism (SSCP) analysis
PCR was carried out as described above except that 0.3 jxl 
[cx-32P]dATP (3,000 Ci/mmol; Amersham, Aylesbury, UK) 
were added to the reaction. Three microliters of the reaction 
product were then mixed with 10 jxl of loading buffer contain­
ing 96% formamide. Samples were denatured at 94°C for 3 min 
and chilled on ice for 5 min, and 2 \jA were loaded onto a 6% 
nondenaturing polyacrylamide gel with and without 10% 
glycerol. Gels were electrophoresed at 5 W (with glycerol) and 
3 W (without glycerol) for 16 hr at room temperature, using 
0.5 x TRIS-borate-EDTA buffer (66 mM TRIS-HC1, 22 mM 
borate, 1 mM EDTA). Gels were dried and films exposed at 
—80°C for 3 days.
Sequ enee ana lysis
PCR products displaying a shift on the SSCP gel were 
sequenced both directly, using the Ampli Cycle sequencing kit 
(Perkin Elmer), and after being cloned into a TA cloning 
vector (pCR II; Invitrogen, San Diego, CA). Sequence compari­
son was based on the EMBL/GenBank data base (access 
number L27211).
Southern blotting
Ten micrograms of DNA were digested by EcoRI (for cell 
lines) or Hindlll (for primary tumors) restriction enzymes, 
separated on a 0.8% agarose gel, transferred onto Hybond N+ 
(Amersham) according to the manufacturer’s protocol and 
hybridized as previously described (Bringuier et al., 1996) with 
a probe of 500 bp corresponding to the entire exon 2 PCR 
product. For loading control, bladder cancer blots were hybrid­
ized with the pHE 5.4 probe corresponding to the ETS 
oncogene, which is located at llq23-24 (de Taisne et a i , 1984). 
For the cell lines, the HPG Ca 2.1 probe (Franke et a l} 1989), 
corresponding to human plakoglobin, localized on 17q21 
(Aberle et al> 1995), was used.
Comparative multiplex PCR
Comparative multiplex PCR was performed essentially as 
described by Walker et al. (1995). The primer pair for exon 2 
and one control primer pair for a gene located on chromosome 
9q were mixed in a PCR reaction and amplified for 30 cycles (1 
min 94°C, 1 min 56°C, 1 min 72°C). PCR products were 
electrophoresed through a 2% agarose gel. After ethidium 
bromide staining, signals fromp!6WK4 and the internal control 
were compared and homozygous deletions scored if the 
p/<5INK4 signal was missing or highly reduced.
RESULTS
p l61NK4 deletions and mutations in cell lines
In 9 of 17 (53%) cell lines, no amplification of exon 2 of the 
4 gene was possible, suggesting homozygous deletions. 
To confirm whether in samples with no PCR product the gene
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F ig u r e  1 -  Homozygous deletions ofp7<5INK4 (exon 2) by South­
ern blotting. Numbers l a 2, 3, 4, 5, 6, 7 and 8, correspond to cell 
lines 647V, TSU (prostatic cell line), VMcub2, 5637, VMcub3} 
SW-780, RT4 and SC aB ER , respectively. Samples 3, 4, 5, 6 and 7 
show homozygous deletions. Numbers 9, 10, 11,12, 13, 14, 15 and 
16 correspond to T24, 2 5 3 J, SD, SW-800, SW1710, RT42, J82 and 
575A bladder cell lines, respectively. Note the homozygous dele­
tions displayed by sam ples 10, 11, 12 and 14.
was indeed homozygously deleted, Southern blot analysis was 
performed. No signal w a s  obtained in 9 of the 17 cell lines 
subjected to this analysis, confirming homozygous deletion
(Fig-1).
We subsequently in v es tig a ted  the presence of point muta­
tions using SSCP analysis, which revealed 2 shifts. One of them 
(SCaBER) has already b e e n  reported (Spruck<?£ al.} 1994). In 
the other (Jon), the s e q u e n c e  alteration at position 454 (codon 
138) did not lead to a n y  amino acid change (AGA AGG, 
Arg Arg).
p l6lNK4 deletions and m u ta t io n s  in bladder tumors 
from the Netherlands
In all of these tum ors, bands of the predicted size (250 and 
340 bp) could be am plified by PCR. However, the presence of 
a low percentage (10—2 5 % ) of normal tissue prevents the 
identification of hom ozygous deletions. Therefore, DNA of 24 
frozen samples were te s te d  for homozygous deletions by 
Southern blot analysis. I n  4 of the 22 TCC samples (18%), 
p j6 ink4 appeared to be homozygously deleted. Multiplex PCR 
on the same samples co n firm ed  deletion in 3 of these samples. 
Therefore, PCR is an a p p ro p r ia te  method to measure p l6 mYA 
deletions, albeit one t h a t  tends to underestimate the fre­
quency. In the 2 SCC s a m p le s ,  no deletions were found.
Band migration sh ifts, as revealed by SSCP analysis, were 
not found in bladder c a n c e r  not associated to bilharziasis, no 
evidence forpZ6TNK4 m u ta t io n  in such tumors being detected.
p l61NK4 deletions and m u ta t io n s  in biiharziasis-associated 
tumors
As shown in Figure 2 , a f te r  comparative multiplex PCR, the 
band specific for p i 61NK4 was often reduced in intensity when 
compared with the c o n tro l .  Indeed, homozygous deletion of 
the p!6WK4 gene was f o u n d  in 23 of 47 (49%) biiharziasis- 
associated bladder carcinom as.
Using SSCP analysis, 3  band migration shifts in the coding
region of p i 6INK4 ( e x o n  2) were found. In one case, the
sequence alteration at p o s it io n  395 of codon 126 did not lead
to any amino acid change (GCG GCA, Ala -> Ala). For the
other 2 tumors (Fig. 3), th e  sequence alterations could not be 
determined.
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Figure 2 -  Multiplex PCR analysis of biiharziasis-associated 
bladder tumors: samples with reduced signal for the p /6INK4- 
specific primer set (upper band) have been considered as deleted 
(lanes 2, 4, 6, 8,10, 11, 14 and 15). The lower band is our internal 
control.
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F ig u r e  3 -  SSCP analysis of exon 2 of the pl6WKA gene. The 2 
migration shifts found in biiharziasis-associated tumors are shown.
(a) SSCP for the 5' part of p!6WK4 exon 2 with a shift in lane 3;
(b) SSCP for the 3' part of p!6WKA exon 2  with a shift in lane 4.
Altogether, 25 of 47 (53%) tumors exhibited a p!6 lUKA 
alteration. The distribution of such alterations among the 
different histological types of tumor is shown in Table I. No 
correlation was found between p!6 imA alteration and either 
grade or stage.
DISCUSSION
In this work, we have studied p l6 im 4 gene alteration in a 
series of 47 biiharziasis-associated bladder tumors from Egypt 
and compared the results with those obtained for a series of 
bladder tumors from the Netherlands. As samples from Egypt 
were paraffin-embedded, deletions were detected by multiplex 
PCR. We first compared this technique with Southern blot and 
found no false-positive cases but one false-negative: only 3 of 
the 4 deletions found by Southern blot could be detected by 
multiplex PCR. Thus, the frequency of deletion we report here 
is an under-estimate rather than an over-estimate. This has 
also been noticed by Williamson et ai (1995). The false- 
negative case was probably due to amplification of the DNA 
from normal tissue, which was more abundant for the DNA 
extracted for Southern blot (up to 25% normal tissue as 
estimated by step section) than in DNA from paraffin- 
embedded material, which was obtained after microdissection. 
Indeed, the results of multiplex PCR were much more clear- 
cut for the biiharziasis-associated bladder tumors than for the 
tumors not associated with bilharziasis. Another explanation 
might be related to the fact that in order to be certain that 
partial deletion and not simple losses of chromosome 9 were
detected, we choose our control PCR set on chromosome 9q, a 
region prone to loss of heterozygozity in TCCs found in 
Western countries but not in biiharziasis-associated bladder 
tumors (Gonzalez-Zulueta et al, 1995).
We believe that the 2 tumors with a shift should be 
considered as mutated since such a shift has been repeatedly 
observed and since direct sequencing is less sensitive than 
SSCP (Knowles and Williamson, 1993). If these shifts were 
caused by polymorphism, the variant sequences would have 
represented at least 50% of the DNA, which is well above the 
detection limit of direct sequencing. Conversely, a mutation 
can be present in only one part of the sample analyzed, which 
makes it undetectable by direct sequencing.
Whatever the real status of these 2 tumors, 3 conclusions can 
be drawn from our work: (i) p !6 lNKA alterations are more 
frequent in cell lines than in primary tumors as described and 
discussed in detail by Spruck et al (1994); (ii) in primary 
bladder tumors (biiharziasis-associated or not), p !6 lNKA dele­
tions are much more frequent than p!6MKA mutations; (iii) 
p!6[NK4 alterations are more frequent in biiharziasis-associated 
bladder tumors than in other bladder tumor types.
Numerous mechanisms have been proposed to explain the 
association of bilharziasis and bladder cancer (WHO, 1983). 
One theory on the possible role of carcinogens is that cancer is 
most likely to occur along with bilharziasis infection. The 
N-nitroso compounds, a potential group of carcinogens widely 
present in the environment and appearing in the urine of 
patients with bilharziasis infection, may be implicated in the 
initiation of bladder cancer (Gentile et al, 1985). Methylation 
in DNA of bilharziasis-infected human bladder tissue has also 
been observed (Badawi et a l , 1992).
The fact that deletions occur more frequently than single 
mutations has been noticed in other tumor types, such as brain 
tumors (Jen et al., 1994; Schmidt et cii, 1994; Giani and 
Finocchiaro, 1994; Walker et a l , 1995), lung cancers (Xiao et 
a i , 1995) and mesothelioma (Cheng et al., 1994). In bladder, 
the rate of homozygous deletions has been found to be higher 
than the rate of mutations. Our data on bladder cancer from 
the Netherlands are thus in agreement with other results 
(Cairns et a l , 1994; Williamson et al, 1995), though the rate of 
homozygous deletion varies from one series to another: 3 of 22 
in our study and 5 of 25 in the study of Cairns et al (1994). 
However, this frequency was estimated at 38% by Williamson 
et al, (1995), who studied a large series of tumors (140 
samples). The lower frequency we found cannot be explained 
by the low sensitivity of the PCR technique, as proposed by 
Williamson et al. (1995), since we have also used Sout 
analysis.
To explain the higher frequency of deletion, it has been 
proposed that inactivation o ip I6 WKA alone does not provide a 
strong selective advantage and that deletion could lead to the 
inactivation of several genes (Jen et a i} 1994); pl5  is, of course, 
an appealing candidate for co-inactivation together withp!6WKA 
since the gene lies immediately beside p l6 lNKA and since both 
proteins exhibit similar biochemical properties. However, in 
bladder tumors, a number of deletions have been found which 
do not involve the p l5  gene, leading to the hypothesis that 
another gene, telomeric to p !6 mKA, is co-deleted (Williamson 
et al, 1995). However, in some tumor types, e.g., esophageal 
SCC (Mori et al., 1994; Zhou et ai, 1994; Igaki et a i , 1995), 
p!6WKA is frequently inactivated by point mutation. It thus 
appears that the selective advantage provided by pl6 lNKA 
inactivation varies according to tissue types.
Experimental evidence thatp !6 lNKA may play a role in tumor 
progression has emerged from studying both sporadic and 
familial malignancies. In familial melanoma, a locus respon­
sible for the disease has been mapped by linkage analysis to 
9p21, a region that harbors the /?76r^ K4 gene as well (Cannon- 
Albright et al., 1992, 1994). Furthermore, an association
lern blot
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TABLE I -p H , 'NKJ STATUS ACCORDING TO HISTOLOGICAL/TOE IN SILHARZIASI|ASSOCIATED AND
NON-ASSOCIATED TUMORS AND BLADDER CANCER CELL LINbb________________
Tumor type
Bilharziasis-associated
tumors
Tumors not associated 
with bilharziasis 
Cell lines
Histological type Homozygousdeletions Mutations
SCC 11/20 0/20
TCC 9/20 2/20
Adenocarcinoma 3/5 0/5
Unknown 0/2 0/2
TCC 4/22 0/22
SCC 0/2 0/2
9/17 1/17
% Total %
Alterations alterations
55% 53% 
53%
60%
0%
'18% 18% 
0%
59% 59%
between germ-line p l6IIViIi4 mutation and familial melanoma 
has been observed in some kindreds, suggesting that the 
pl& ink4 gene js an inherited melanoma susceptibility gene
(Ohta etal, 1994; Kamb et al, 1994ft). Hussussian et al. (1994) 
have indeed shown that in 9/15 families with inherited 
melanoma linked to 9p21, 6 p !6 lNK4 mutations co-segregate 
with the occurrence of melanoma (Hussussian et al, 1994). A 
somatic mutation (Pro-81-Leu) was also detected in a tumor 
from an individual with the (Arg-87-Pro) germ-line mutation 
(Hussussian etal, 1994). A similar study on 15 Dutch families 
revealed a 19 bp exon 2 deletion in 13 kindreds (Gruis et al,
1995). Surprisingly, ail of the kindreds carried the same 
deletion, suggesting a common ancestry of the affected popula­
tion. Alternatively, none of the previously described melanoma- 
associated mutations was found in a study carried out on 17 
Australian melanoma kindreds, with one family exhibiting an 
exon 1 mutation not described so far. This was shown to 
co-segregate with melanoma and to cause an amino acid 
substitution (Arg-24-Pro) (Holland et a l , 1995). Sporadic 
cutaneous melanoma accounts for approximately 90% of all 
cases of melanoma and probably arises as an cumulative result 
of genetic defects (Herlyn, 1993). In a melanoma cell line 
established from an individual patient, it has been shown that 
deletion of 9p21 can occur before metastasis in sporadic 
melanoma (Glendening et al, 1995).
The most interesting finding of our study is the high deletion 
rate in tumors from Egypt. In non-small cell lung cancer, it has 
been suggested thatp!6mK4 alteration is a late event during the 
carcinogenic process (Okamoto et al, 1995). If this is also true 
for bladder, this could contribute to the high frequency of 
alteration found in bilharziasis-associated bladder tumors as 
these are generally detected at an advanced stage. However, 
we do not favor this explanation since we did not observe any
increased frequency of alteration along with either grade or 
stage in such samples. The increased frequency of p ! 6 WK4 
alteration thus appears to be truly associated with schistosome 
infestation. Actually and while our work was in progress, a 
study of genetic alterations in SCCs has been published 
(Gonzalez-Zulueta et al, 1995), in which /?i<5iNK4 alterations 
were found in 6 of 9 SCCs from Egypt. The results we have 
obtained on a larger series confirm the high prevalence of 
p l6 WKA alterations in bilharziasis-associated bladder tumors. 
Gonzalez-Zulueta et al (1995) suggest that p ! 6 lNKA deletions 
might be a part of a pathway specific for SCC development. 
Indeed, they have also analyzed 3 SCCs from Sweden and 
found pl6WKA alteration in 2, Our data do not support this 
hypothesis since: (/) the 2 SCCs from the Netherlands we have 
analyzed showed no pJ6imA alteration; (ii') in bilharziasis- 
associated bladder tumors, p l6 mKA alterations were not re­
stricted to SCC but were found with a similar frequency in any 
type of tumor, According to our results, /?/(5,NK4 alteration is 
rather associated with a specific etiology (the presence of 
schistosome eggs in the bladder wall) than with a specific 
histological type.
Since D-type cyclin, CDK4,/;/(51NM and the retinoblastoma 
(RB) protein act via the same pathway, it has been proposed 
that inactivation or activation of one of these elements would 
deregulate the Gi transition. Indeed, aberrations of p ! 6 lNKA 
and RB occur in distinct subsets of cell lines (Aagaard et al.,
1995). The fact that in bilharziasis-associated bladder tumors 
RB expression is often conserved, whereas p l 6 MKA is often 
inactivated, supports this hypothesis. The study of bladder 
cancer samples from the NethcrlandvS, which we analyzed for 
activation of cyclin D1 and inactivation of p ! 6 WK4 and RB, 
provides indications in favor of this hypothesis (Bringuier et al,
1996).
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